Table 3. Comparison of BCMA-targeted... | American Society of Hematology

Table 3.

Comparison of BCMA-targeted modalities in MM

	ADCs	Bispecific antibodies/BiTEs	CAR T cells
Off the shelf	Yes	Yes	No*
Logistics/ease of administration	Easiest, outpatient dosing†	More difficult, requires hospitalization for initial dosing, familiarity with CRS/neurotoxicity management	Most difficult, requires leukapheresis, specialty center with CAR T expertise, delays owing to manufacturing, hospitalization, familiarity with CRS/neurotoxicity management
Repeated dosing required	Yes	Yes	No
Dependent on patient T-cell “fitness”	No	Yes	Yes
Unique toxicities	Infusion reactions, toxin dependent	CRS, neurotoxicity	CRS, neurotoxicity
Toxicity duration	Ongoing	Ongoing	Usually 7-21 d
Durable clinical activity seen	Yes	Yes	Yes

	ADCs	Bispecific antibodies/BiTEs	CAR T cells
Off the shelf	Yes	Yes	No*
Logistics/ease of administration	Easiest, outpatient dosing†	More difficult, requires hospitalization for initial dosing, familiarity with CRS/neurotoxicity management	Most difficult, requires leukapheresis, specialty center with CAR T expertise, delays owing to manufacturing, hospitalization, familiarity with CRS/neurotoxicity management
Repeated dosing required	Yes	Yes	No
Dependent on patient T-cell “fitness”	No	Yes	Yes
Unique toxicities	Infusion reactions, toxin dependent	CRS, neurotoxicity	CRS, neurotoxicity
Toxicity duration	Ongoing	Ongoing	Usually 7-21 d
Durable clinical activity seen	Yes	Yes	Yes

Allogeneic “off-the-shelf” CAR T cells are in development for MM, but no clinical data are available yet.

†

The anti-BCMA ADC GSK2857916 does require close monitoring with an ophthalmologist owing to corneal toxicity; other non–MMAF-containing ADCs should not have this issue.

View Large

This Feature Is Available To Subscribers Only